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B7-H4 inhibits T-cell activation and is widely expressed by solid neoplasms. 
We have recently demonstrated that 
the expression of B7-H4 on the surface 
of malignant cells in vivo is inducible, 
and that novel anti-B7-H4 recombinant 
antibodies can reverse the inhibition of 
tumor-specific T cells. Thus, antibod-
ies targeting the B7-H4 pathways may 
extend the survival of cancer patients 
by restoring T cell-mediated antitumor 
responses.
Ovarian neoplasms stimulate endog-
enous immune responses that can result 
in tumor rejection or progression, depend-
ing on which subset of immune cells 
becomes prevalent within the tumor 
microenvironment. Indeed, while tumor-
infiltrating CD8+ effector T cells (Teffs) 
are associated with favorable disease out-
come,1 other cell subsets such as regula-
tory T cells (Tregs) and tumor-associated 
macrophages (TAMs) promote disease 
progression via multiple mechanisms, 
including the secretion of immunosup-
pressive molecules such as interleukin-10 
(IL-10) and indoleamine 2,3-deoxygenase 
(IDO), as well as the expression of inhibi-
tory molecules such as cytotoxic T lym-
phocyte-associated protein 4 (CTLA4), 
programmed cell death 1 (PDCD1, 
best known as PD-1), and V-set domain 
containing T cell activation inhibitor 1 
(VTCN1, best known as B7-H4).2 The 
tumor microenvironment can therefore 
support immune escape by orchestrating 
a complex network of immunosuppressive 
cells and mediators that interfere with the 
generation and clonal expansion of antitu-
mor Teffs.
The clinical relevance of strategies 
for the inhibition of B7-H4 in patients 
affected by malignant conditions or 
autoimmune diseases has previously 
been established. The overexpression of 
B7-H4 correlates indeed with advanced 
disease stage and poor prognosis in can-
cer patients,3,4 as well as with increased 
tumorigenicity and invasiveness in cancer 
cells.5 B7-H4 exists in a soluble variant 
and as a transmembrane protein expressed 
on the surface of antigen-presenting cells 
(APCs). Upon interaction with a hith-
erto unknown ligand (which we refer to 
as B7-H4L*),6 B7-H4 inhibits the activa-
tion and proliferation of antigen-specific 
Teffs (Fig. 1). These properties confer a 
profound translational value to B7-H4 
in the context of anticancer immuno-
therapy.  However, until recently B7-H4 
was thought to be localized mainly in the 
cytoplasm of ovarian cancer cells,6 which 
would be incompatible with the use of 
B7-H4-specific monoclonal antibodies.
We investigated the expression of 
B7-H4 on the surface of established ovar-
ian cancer cell lines and primary ovarian 
carcinoma cells obtained from patient 
ascites and solid neoplastic lesions.7 As 
expected, B7-H4 was poorly expressed on 
the surface of ovarian cancer cell lines. 
Conversely, B7-H4 was detected in sig-
nificant amounts on the surface of pri-
mary malignant cells from ovarian cancer 
patients. To further explore the expression 
pattern of B7-H4 in vivo, we inoculated 
mice with an ovarian cancer cell line that 
does not express B7-H4 on its surface, 
but contains cytoplasmic levels of B7-H4 
that are detectable by immunoblotting. 
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The expression of B7-H4 on the surface of 
these cells increased upon an in vivo pas-
sage, but was rapidly downregulated when 
harvested cells were placed in culture. 
These data are consistent with previous 
findings by Chen and colleagues, dem-
onstrating that TAM-derived factors can 
promote the expression of B7-H4 on the 
surface of Lewis Lung carcinoma (LLC) 
cells in vivo.8 Zhang and colleagues also 
demonstrated that the levels of B7-H4 
at the plasma membrane, but not within 
the nucleus or the cytoplasm, inversely 
correlate with the amount of lympho-
cytes infiltrating renal cell cancer (RCC) 
lesions, providing a direct link between 
the expression of B7-H4 on the surface 
of malignant cells and Teff inhibition.9 
Altogether, these results indicate that the 
amounts of B7-H4 on the surface of can-
cer cells increase in response to microenvi-
ronmental cues and may promote immune 
evasion. The expression of B7-H4 at the 
surface of both malignant and tumor-
infiltrating immunosuppressive cells 
establishes a rationale for the development 
of therapeutic approaches based on the 
targeting of B7-H4.
Recombinant single-chain variable 
fragments (scFvs) allow for the targeting 
of selected cell populations both as naked 
molecules and upon conjugation to endo-
toxins, nanoparticles, radioisotopes, or 
protein domains. Moreover, scFvs can be 
fused to T cell-relevant signaling domains 
to generate so-called chimeric antigen 
receptors (CARs), molecules that pro-
vide T cells with the ability to respond to 
antigens in the absence of MHC presenta-
tion. Combining protein- and cell-based 
screening approaches, we isolated scFvs 
specific for human B7-H4 from a novel 
yeast display scFv library that had been 
created from B cells found in the ascites 
and peripheral blood mononuclear cells 
(PBMCs) of ovarian cancer patients. In 
particular, scFvs were selected based on 
their affinity for soluble and cell-surface 
B7-H4, as well as on their ability to reverse 
T-cell inhibition. We generated in vitro 
model systems in which B7-H4 molecules 
expressed either in cis on APCs or can-
cer cells, or in trans on tumor-polarized 
macrophages (third party inhibition), 
could inhibit the activation of tumor-
specific T cells. Using these systems, we 
demonstrated that an anti-B7-H4 scFv 
(called 3#68) could fully reverse T-cell 
inhibition as mediated by recombinant 
B7-H4, by peptide-pulsed B7-H4+ APCs, 
by tumor-polarized B7-H4+ macrophages 
admixed with B7-H4- cancer cells, as 
well as by B7-H4-transduced malignant 
cells. Another anti-B7-H4 scFv, namely 
3#54, exerted a quantitatively reduced 
but qualitatively similar activity. Con-
sistently, 3#68 was more efficient than 
3#54 in delaying tumor growth in a 
humanized mouse model of ovarian can-
cer. These results not only confirm that 
B7-H4 exerts potent immunosuppres-
sive effects as it inhibits T cell-mediated 
antitumor responses, but also support the 
use of 3#68 for blocking B7-H4 within 
the tumor microenvironment and hence 
Figure 1. Blocking B7-H4 in the tumor microenvironment with specific antibodies potentiates antitumor immune responses. t cells recognize antigens 
complexed with MHC class I (MHCI) molecules on the surface of antigen-presenting cells (aPCs) and some cancer cells, through the t-cell receptor (tCr). 
the binding of B7-H4 expressed by malignant cells, aPCs and tumor-associated macrophages (taMs) to a putative ligand (B7-H4L*) on the surface of 
t cells significantly impairs the activation of the latter within the tumor microenvironment. the simultaneous blockade of B7-H4 on various cellular 
components of the tumor mass, as obtained with specific monoclonal antibodies, can revert t-cell inhibition and hence favor the elicitation of t cell-
mediated antitumor responses.
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favoring the (re)activation of tumor-spe-
cific T cells (Fig. 1).
A major obstacle against the develop-
ment of effective anticancer immunother-
apy stems from the inadequate stimulation 
of tumor-specific Teffs, at least in part 
reflecting the lack of T-cell co-stimulation 
within the tumor microenvironment. 
Consistent with this view, the simultane-
ous targeting of multiple immunological 
checkpoints such as those mediated by 
CTLA4 and PD-1 has recently yielded 
impressive clinical results among mela-
noma patients.10 Monitoring the inhibi-
tion of B7-H4 signaling in vivo together 
with that of other immunosuppressive 
pathways might improve our understand-
ing of the mechanisms that underlie 
tumor-dependent T-cell inhibition. We 
propose that combining the targeting of 
B7-H4 with other immunotherapeutic 
strategies, including adoptive T-cell trans-
fer, could functionally modulate diverse 
cellular components of the tumor micro-
environment and hence potentiate T cell-
mediated antitumor immune responses.
Disclosure of Potential Conflicts of Interest
The authors have no potential conflicts 
of interest to disclose.
 References
1. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty 
PA, Massobrio M, Regnani G, Makrigiannakis 
A, Gray H, Schlienger K, Liebman MN, et al. 
Intratumoral T cells, recurrence, and survival in epi-
thelial ovarian cancer. N Engl J Med 2003; 348:203-
13; PMID:12529460; http://dx.doi.org/10.1056/
NEJMoa020177
2. Torres MP, Ponnusamy MP, Lakshmanan I, Batra 
SK. Immunopathogenesis of ovarian cancer. Minerva 
Med 2009; 100:385-400; PMID:19910891
3. Kryczek I, Wei S, Zhu G, Myers L, Mottram P, 
Cheng P, Chen L, Coukos G, Zou W. Relationship 
between B7-H4, regulatory T cells, and patient 
outcome in human ovarian carcinoma. Cancer Res 
2007; 67:8900-5; PMID:17875732; http://dx.doi.
org/10.1158/0008-5472.CAN-07-1866
4. Wei J, Loke P, Zang X, Allison JP. Tissue-specific 
expression of B7x protects from CD4 T cell-medi-
ated autoimmunity. J Exp Med 2011; 208:1683-
94; PMID:21727190; http://dx.doi.org/10.1084/
jem.20100639
5. Cheng L, Jiang J, Gao R, Wei S, Nan F, Li S, Kong 
B. B7-H4 expression promotes tumorigenesis in ovar-
ian cancer. Int J Gynecol Cancer 2009; 19:1481-
6; PMID:19955922; http://dx.doi.org/10.1111/
IGC.0b013e3181ad0fa2
6. Kryczek I, Zou L, Rodriguez P, Zhu G, Wei S, 
Mottram P, Brumlik M, Cheng P, Curiel T, Myers L, 
et al. B7-H4 expression identifies a novel suppressive 
macrophage population in human ovarian carcinoma. 
J Exp Med 2006; 203:871-81; PMID:16606666; 
http://dx.doi.org/10.1084/jem.20050930
7. Dangaj D, Lanitis E, Zhao A, Joshi S, Cheng Y, 
Sandaltzopoulos R, Ra HJ, Danet-Desnoyers G, 
Powell DJ Jr., Scholler N. Novel recombinant human 
B7-H4 antibodies overcome tumoral immune escape 
to potentiate T cell anti-tumor responses. Cancer 
Res 2013; Forthcoming; PMID:23722540; http://
dx.doi.org/10.1158/0008-5472.CAN-12-3457
8. Chen C, Qu QX, Shen Y, Mu CY, Zhu YB, Zhang XG, 
Huang JA. Induced expression of B7-H4 on the sur-
face of lung cancer cell by the tumor-associated mac-
rophages: a potential mechanism of immune escape. 
Cancer Lett 2012; 317:99-105; PMID:22108530; 
http://dx.doi.org/10.1016/j.canlet.2011.11.017
9. Zhang L, Wu H, Lu D, Li G, Sun C, Song H, Li J, 
Zhai T, Huang L, Hou C, et al. The costimulatory 
molecule B7-H4 promote tumor progression and 
cell proliferation through translocating into nucleus. 
Oncogene 2013; Forthcoming; PMID:23318460; 
http://dx.doi.org/10.1038/onc.2012.600
10. Wolchok JD, Kluger H, Callahan MK, Postow 
MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan 
CE, Gordon RA, Reed K, et al. Nivolumab plus 
ipilimumab in advanced melanoma. N Engl J Med 
2013; 369:122-33; PMID:23724867; http://dx.doi.
org/10.1056/NEJMoa1302369
 
